Forte Biosciences to Host R&D Day December 3, 2024
Forte Biosciences (NASDAQ: FBRX) has announced an upcoming R&D Day scheduled for December 3, 2024 at 4:30 p.m. ET. The event will spotlight the development of FB102 across autoimmune indications, featuring prominent experts in celiac disease, vitiligo, and alopecia areata.
Distinguished speakers include Prof. Jason Tye-Din from Walter and Eliza Hall Institute, Prof. Christopher Ma from University of Calgary, and Prof. David Rosmarin from Indiana University School of Medicine. These thought leaders will share insights on their respective fields of expertise in autoimmune-related diseases.
Forte Biosciences (NASDAQ: FBRX) ha annunciato un Giorno di Ricerca e Sviluppo previsto per il 3 dicembre 2024 alle 16:30 ET. L'evento metterà in luce lo sviluppo di FB102 per le indicazioni autoimmuni, con la partecipazione di esperti di spicco nella malattia celiaca, nel vitiligine e nell'alopecia areata.
I relatori di prestigio includono Prof. Jason Tye-Din dell'Istituto Walter e Eliza Hall, Prof. Christopher Ma dell'Università di Calgary e Prof. David Rosmarin della Scuola di Medicina dell'Università dell'Indiana. Questi leader di pensiero condivideranno intuizioni sui rispettivi campi di competenza nelle malattie autoimmuni.
Forte Biosciences (NASDAQ: FBRX) ha anunciado un próximo Día de I+D programado para el 3 de diciembre de 2024 a las 4:30 p.m. ET. El evento destacará el desarrollo de FB102 en indicaciones autoinmunes, con la participación de expertos destacados en la enfermedad celíaca, vitiligo y alopecia areata.
Los oradores distinguidos incluyen al Prof. Jason Tye-Din del Instituto Walter y Eliza Hall, al Prof. Christopher Ma de la Universidad de Calgary y al Prof. David Rosmarin de la Escuela de Medicina de la Universidad de Indiana. Estos líderes de opinión compartirán sus conocimientos sobre sus respectivos campos de experiencia en enfermedades autoinmunes.
포르테 바이오사이언스(NASDAQ: FBRX)가 2024년 12월 3일 오후 4시 30분 ET로 예정된 R&D 데이를 발표했습니다. 이 행사는 셀리악병, 백반증 및 탈모증과 같은 자가면역 질환에 대한 FB102의 개발을 조명합니다.
저명한 연사로는 월터와 엘리자 홀 연구소의 자슨 타이-딘 교수, 캘거리 대학의 크리스토퍼 마 교수, 인디애나 대학교 의과대학의 데이비드 로스마린 교수가 포함되어 있습니다. 이들 사상가는 자가면역 질환 관련 각 분야에서 귀중한 통찰력을 공유할 것입니다.
Forte Biosciences (NASDAQ: FBRX) a annoncé un prochain Jour de R&D prévu pour le 3 décembre 2024 à 16h30 ET. Cet événement mettra en lumière le développement de FB102 pour les indications auto-immunes, avec la participation d'experts de renom dans le domaine de la maladie cœliaque, du vitiligo et de l'alopécie areata.
Les conférenciers distingués incluent Prof. Jason Tye-Din de l'Institut Walter et Eliza Hall, Prof. Christopher Ma de l'Université de Calgary et Prof. David Rosmarin de l'École de Médecine de l'Université d'Indiana. Ces leaders d'opinion partageront leurs idées sur leurs domaines d'expertise en matière de maladies auto-immunes.
Forte Biosciences (NASDAQ: FBRX) hat einen bevorstehenden F&E-Tag angekündigt, der für den 3. Dezember 2024 um 16:30 Uhr ET angesetzt ist. Die Veranstaltung wird die Entwicklung von FB102 bei autoimmunen Indikationen ins Rampenlicht rücken und prominente Experten für Zöliakie, Vitiligo und Alopezie areata präsentieren.
Zu den namhaften Sprechern gehören Prof. Jason Tye-Din vom Walter und Eliza Hall Institute, Prof. Christopher Ma von der Universität Calgary und Prof. David Rosmarin von der Indiana University School of Medicine. Diese Vordenker werden Einblicke in ihre jeweiligen Fachgebiete zu autoimmunen Krankheiten teilen.
- None.
- None.
The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute, Prof. Christopher Ma MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary and Prof. David Rosmarin, MD, Chair of the Department of Dermatology at the School of Medicine,
Use the link below to register for the event:
https://lifescievents.com/event/fortebiorx/
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Source: Forte Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125861743/en/
LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Source: Forte Biosciences, Inc.
FAQ
When is Forte Biosciences (FBRX) hosting its R&D Day in 2024?
What will be the main focus of Forte Biosciences (FBRX) R&D Day 2024?
Which key experts will be speaking at Forte Biosciences (FBRX) R&D Day?
What medical conditions will be discussed at Forte Biosciences (FBRX) R&D Day 2024?
